Explanatory Note on the Withdrawal of ICH Q1F for the ICH Website
ICH Q1 F Stability Data Package for Registration Applications in Climatic Zones III and IV defined storage conditions for stability testing in countries located in Climatic Zones III (hot and dry) and IV (hot and humid), i.e. countries not located in the ICH regions and not covered by ICH Q1 A (R2) Stability Testing for New Drug Substances and Drug Products. ICH Q1 F described harmonised global stability testing requirements in order to facilitate access to medicines by reducing the number of different storage conditions. In the course of the discussions which led to the development of the guideline, WHO conducted a survey amongst their member states to find consensus on 30°C/65% RH as the long-term storage conditions for hot and humid regions. As no significant objections were raised in this survey, 30°C/65% RH was defined as the long-term storage condition for Climatic Zone III/IV countries in ICH Q1F. The document was adopted by the ICH Steering Committee in February 2003 and subsequently implemented in the ICH regions.
However, based on new calculations and discussions, some countries in Climatic Zone IV have expressed their wish to include a larger safety margin for medicinal products to be marketed in their region than foreseen in ICH Q1F. As a consequence, several countries and regions have revised their own stability testing guidelines, defining up to 30°C/75 % RH as the long-term storage conditions for hot and humid regions. Due to this divergence in global stability testing requirements, the ICH Steering Committee has decided to withdraw ICH Q1F and to leave definition of storage conditions in Climatic Zones III and IV to the respective regions and WHO.
In assessing the impact of the withdrawal of ICH Q1F on intermediate testing conditions defined in ICH Q1A (R2), the decision was reached to retain 30°C/65%RH. However, regulatory authorities in the ICH regions have agreed that the use of more stringent humidity conditions such as 30°C/75% RH will be acceptable should the applicant decide to use them.作者: 木槿 时间: 2011-11-23 16:34
ICH Q1 F的解释还是相当明白的,怎么没有看一下呢?作者: 耗子=== 时间: 2011-11-23 16:35
several countries and regions have revised their own stability testing guidelines, defining up to 30°C/75 % RH as the long-term storage conditions for hot and humid regions. Due to this divergence in global stability testing requirements, the ICH Steering Committee has decided to withdraw ICH Q1F and to leave definition of storage conditions in Climatic Zones III and IV to the respective regions and WHO.作者: 耗子=== 时间: 2011-11-23 16:38 标题: 回复 #14 star#room 的帖子
cuturl('http://apps.who.int/prequal/info_general/documents/stability/Stability_Requirements.pdf')
New requirement
With effect from September 2011, when evaluating applications WHO will assume that all the medicines prequalified will be used in all sub‐zones of Climatic Zones III and IV, unless otherwise properly justified by the applicant and confirmed by WHO (see diagram below with supply data per climatic zone). Therefore, in order to safeguard product quality throughout its entire intended shelf‐life, stability studies under the conditions defined for Climatic Zones IVb should be performed and the data submitted, i.e. the shelf‐life should be established based on complete* long‐term data at 30?C ±2?C/75% RH ±5% RH.
Furthermore, in order to aid procurement decisions, it is proposed that the conditions under which stability studies were performed and the established shelf‐life, will be included in the WHO List of Prequalified Medicinal Products
*”Complete” refers to the length of data required at the time of dossier submission.作者: tie8 时间: 2011-11-23 16:50